So far, my only Swedish purchase hit exactly the right company with an average price of 23.54 SEK. Geno has taken over the number one spot in the balanced portfolio by a landslide. I’ve tried to find news and at least some information about the recent days’ rise, but practically nothing has happened. Well, there aren’t many resistance levels if some good news comes out, because the ATH has just been surpassed
I’m very tempted to sell before the Q2 report and buy back (possibly) cheaper after a bad report, but I’m trying to restrain myself from gambling. Geno has earned the top spot in the portfolio and gets to keep it with these performances. I’ll add a bit more if it drops significantly.
I jumped into Genon when the price was 6 SEK. Over the years, I’ve gradually reduced my holdings and invested in other stocks. About 10% of the original amount remains. It would be hindsight to say I shouldn’t have sold anything. That’s investing for you. Luckily, I’ve found some good stocks to replace them.
I’m still wondering how I managed to buy this on May 27th at a rate of 36 kr I probably meant to set the limit price to 26 kr. It’s a long wait to even break even
There’s no need to stress, Geno has an incredibly strong scaling, meaning a very large portion of additional sales goes straight to the bottom line. And sales are sure to grow.
Well, another halt and ATH just broke. Redeye has a big impact here too. A real Inderes effect in Swedish Now I’m a bit anxious because I didn’t have time to tank under 30 kronor yesterday morning.
Edit: that was yesterday’s halt, but still +10% in the glass.
Genovisin “own” bank, Penser Bank, has bought 100k shares, and board member Torben Jörgensen has just bought an additional 20k @ 34.85 SEK, on top of the 40k @ 23.5 SEK he bought in May.
I guess only Premium members can see Redeye’s model portfolio (top picks). Investor membership costs 349 SEK/month.
I haven’t regretted the membership for a moment; it provides good analysis and picks.
The monthly fees I’ve paid have returned many times over.
For example, at the beginning of June, I bought Xspray Pharma when they added it to their portfolio. The purchase price was 120 SEK, and now the share price is 200 SEK.
By the way, tomorrow is the Q2 earnings report, which I had personally marked in my calendar as likely to be a weak result And that it would grow towards the end of the year. Let’s see what happens.
I probably meant to set the limit price to 26 kr. It’s a long wait to even break even 